Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events. While management believes its assumptions, expectations and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.
The company's actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and Risk Factors sections of the company's Form 10-K for the year 2021, which was filed March 11th, 2022, and its other filings with the SEC, which are available on the Investor Relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which company management assesses and operates the business.
These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss, and are not substitutes for or superior to measures of financial performance in conformity with GAAP. Today's conference is being recorded. At this time, it's my pleasure to turn the call over to Lisa Conte, Jaguar Health's Founder, President, and Chief Executive Officer. Lisa, the floor is yours.
Thank you. Thank you for those very comprehensive forward-looking statements. Welcome all. As you just heard, my name is Lisa Conte, and I am the Founder, President, and CEO of Jaguar Health and our wholly owned subsidiary in the United States, Napo Pharmaceuticals. I'm also the Chairman of the board of Napo Therapeutics, the corporation we established in Milan, Italy last year, to which we granted an exclusive license to crofelemer in the European territory. Specifically, Napo Therapeutics is initially pursuing a rare disease business model based on the orphan designation of crofelemer for Short Bowel Syndrome, which I'm going to refer to as SBS throughout this talk. Jaguar is the majority shareholder of Napo Therapeutics, providing equity interest value to Jaguar as well as the typical license terms, which we'll talk about in a moment.
I'm going to begin today with a few brief updates, and then Carol Lizak, Jaguar's Chief Financial Officer, will provide a recap of key financial results for the first quarter of 2022. As you'll hear from Carol, and I am so pleased to steal her thunder at the moment, we are reporting Mytesi net revenue of approximately $2.6 million in the first quarter of 2022, representing an approximate 24% increase over Mytesi net revenue in the fourth quarter of 2021, which was approximately $2.1 million, and approximately a 112% increase over Mytesi net revenue in the first quarter of 2021, which was approximately $1.2 million.
These increases largely represent the important and continuing realization of the benefits from both a financial perspective and so importantly, from the standpoint of improved patient access of the transition Jaguar completed this past January to distributing Mytesi through a closed network of specialty pharmacies rather than to wholesalers that resell the product to retail pharmacies. A transition that has decreased our distribution costs and improved our gross to net ratio to 76% in this first quarter of 2022, an improvement from approximately 27% in the first quarter of 2021. Having the net and the gross track much more closely together in Q1 2022.
After Carol, whose thunder I just stole, we'll hear from Ian Wendt, Jaguar's Chief Commercial Officer, about several new Mytesi-related commercial initiatives that we're very excited about, including a telehealth initiative to continue to educate and serve the HIV community, and about commercial efforts underway for Canalevia -CA1, our prescription drug for the treatment of induced diarrhea, which I'm going to refer to as CID, chemotherapy-induced diarrhea in dogs. The product received conditional approval from the FDA this past December, and became commercially available to veterinarians and their clients in the U.S. to provide comfort and relief to their canine patients at the end of April 2022, just last month.
An estimated 9 million dogs were acquired by the US households during the pandemic, according to the American Pet Products Association, bringing the total number of dogs in the United States to 108 million, which is roughly one dog for every three humans in the country. 25% of dogs will deal with a tumor at some point. 50% of dogs over 10 years of age will be diagnosed with cancer. Addressing CID is key to canine survivability from cancer, as well as for supporting dog owners in the decision to seek cancer care for their dogs. Dogs are remarkably predictive of and similar to the human CID situation. As with human cancer patients, dogs go off their disease-modifying chemotherapy approximately 40% of the time due to diarrhea, meaning these dogs cannot complete their therapeutic dose of chemotherapy because of diarrhea.
Extremely relevant in the dog market, though, is the comfort factor for the dog, a key factor influencing a dog parent's decision about whether to treat the dog's cancer. The quality of life for the whole family is a key factor as well. A dog losing control on the rug, bed, couch is an important consideration for the family household. While we do not provide guidance, we do feel the total addressable dog CID market could be about the size of the total addressable market for the human HIV specialty market, and provides much greater predictability of this gross to net ratio since dog parents are typically paying out of pocket for treatment and medications, so we don't have the variability in the chargebacks as you have in the human situation.
Education about the devastating impact to the patient of diarrhea and cancer therapy builds awareness regardless of whether the patient is a human or a dog. While we're on the topic of canine cancer, I wanna take a moment to invite all of you to the in-person special media event and performance in New York City on Monday, May 23rd, from 12:30 P.M. to 2:30 P.M. Eastern Time, to celebrate the launch of the Jaguar Health Canine Cancer Take CHARGE Initiative. CHARGE is an acronym for Canine Health and Registry Exchange. The goal is to establish the first-ever US canine cancer national registry and cancer care index to assess the prevalence and incidence of cancer in dogs. The mission is important because protecting dogs from cancer begins with knowing its impact by breed, by type, by age, by gender, and geography, location.
We will be revealing data at the event from the first nationwide Gallup survey of pet owners, which is an important media hook, addressing their experience with canine cancer, as well as the registry itself that is based on the analysis of thousands of canine medical records, anonymous canine medical records. The data may also provide insights to help better understand cancer in humans and the importance of managing side effects in humans in human cancer therapy. You can RSVP online for this in-person outdoor event on the Events and Presentations page of the Investor section of Jaguar's website, or you can RSVP by sending an email to takechargersvp@togorun.com, T-O-G-O-R-U-N.com. If you're not able to join us in person in New York on May 23rd, virtual access will, of course, be available.
This is an event for all interested parties, dog owners, veterinarians, veterinary oncologists, investors, the media, anyone who is concerned about addressing and managing cancer in our four-legged best friends. The event is taking place on the first annual National Canine Cancer Awareness Day. Human and doggy treats will be served, and the event will feature presentations by Jaguar, by a collaborating partner, TogoRun. It's our wonderful PR firm that is supporting this effort. By Gallup, the leading survey organization that conducted our national poll of dog owners about canine cancer. From Dr. Sue, the famous cancer vet who has enormous online and offline following. Very excitingly, the Take CHARGE launch event will also feature performances by a truly amazing lineup of Broadway stars who are also dog lovers and wanna bring awareness to this activity.
A lineup that we expect to include Academy Award-nominated actor and playwright Chazz Palminteri, actress and producer Gianna Palminteri, his wife, actor, director, and producer Richard Blake, Grammy-winning and Tony-nominated actress Jenn Colella, recently Tony-nominated actress as of yesterday, Shoshana Bean, Broadway actor and singer Bobby Conte, who happens to be my son, Tony-nominated actress, singer, and songwriter Orfeh, her husband, Tony-nominated actor and singer Andy Karl, and Broadway actor, singer, and film producer Manu Narayan. We're very excited about this event. It'll be educational, it'll be entertaining, and we would be thrilled to have you attend. 2022 is Jaguar's Year of the Dog, and we're praying for good weather on the 23rd. As a reminder, crofelemer under the trade name Mytesi is our plant-based FDA-approved antidiarrheal drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.
This is the current indication. Crofelemer is also the focus for human pipeline indications on the clinical development front, each expected to create transformative value for Jaguar in the next 12-15 months. This includes prophylaxis of cancer therapy-related diarrhea and short bowel syndrome, SBS, which is a catastrophic health situation for which crofelemer has received orphan drug designation in the U.S. and the European Union. Crofelemer is also the active ingredient, by the way, in Canalevia-CA1, the dog product. Enrollment is continuing for the OnTarget study, our phase III trial of crofelemer for CTD, cancer therapy-related diarrhea, in humans. We're aiming to complete 256 patient enrollments by the first half of 2023.
As I mentioned during the last webcast on March 14th, we're in the process of adding additional clinical trial sites both in the United States and outside the U.S. to help ensure patient enrollment despite COVID-related restrictions and global unrest and the diversity of the tumor types in the patients. The successful completion of this pivotal trial will result in a supplemental new drug application filing for the same formulation as the currently commercialized crofelemer Mytesi. Mytesi is of course already approved for chronic use in people with HIV/AIDS and has a full FDA-compliant supply chain in place from the rainforest to our specialty pharmacy distribution network across the U.S. As a reminder, safety and manufacturing are the two most common reasons why new drug applications fail.
Hence, we spent much care and communication with the FDA in the design and execution of this final clinical and regulatory step to bring crofelemer to cancer patients suffering with diarrhea. Diarrhea is the most common side effect in cancer patients. As mentioned, an estimated 40% of patients with CTD discontinue their chemotherapy or their targeted therapy, their life-saving cancer treatment because of diarrhea. This is not your garden variety traveler's diarrhea. Patients are often hospitalized for CTD, dehydration, electrolyte imbalance, and organ failure, and some patients have even died from the impact of their diarrhea during clinical investigation by targeted therapy manufacturers. Our second core development focus for crofelemer in 2022 is the orphan-designated disease SBS. We expect investigator-initiated proof-of-concept studies for crofelemer for SBS and congenital diarrheal disorders, CDD, a rare inherited disease causing a lifelong intestinal failure.
We expect these investigative proof-of-concept studies to be completed in 2022 and others continuing into 2023 at sites in the Middle East and Europe, supporting the potential for expanded patient access in 2023 through programs in Europe for these devastating and catastrophic diseases and health situations for these patients. Expanded patient access is a reimbursed program throughout Europe. SBS and CDD clinical development efforts are being led by the skilled, focused, and rare disease experienced Napo Therapeutics management team in Italy, a leadership team comprised of managing director, chief medical officer, and a head of regulatory and quality.
As another reminder, we established Napo Therapeutics in Europe because the European Medicines Agency, the EMA, the equivalent to the FDA in the United States, is committed to enabling reimbursed early access to new medicines with orphan drug status, underscoring the important unmet medical need to patients through early access programs. Participation in an early access program would potentially provide patients with access to crofelemer as early as 2023, and thereby potentially impacting in a positive way their morbidity, mortality, and the cost of care for this chronic indication, SBS, that has no good therapeutic options. Both CDD and SBS patients with intestinal failure typically require parenteral nutrition up to 20 hours a day, seven days a week to survive at tremendous cost with tremendous accompanying medical complications. Huge impact on any sort of quality of life.
Ability to decrease the parenteral nutrition requirement by even 20% would provide a huge medical and quality of life improvement. In a typical rare disease business model, these substantial benefits are highly valued for a relatively small patient population. The global SBS market of an estimated 40,000-60,000 patients worldwide is expected to reach $4.6 billion by 2027, according to a third-party report from Vision Research Reports. Napo Therapeutics operates under an exclusive license to crofelemer from Jaguar, for which Jaguar receives typical license payments, including an upfront payment, milestone payments, royalties, and transfer pricing of crofelemer. Jaguar also receives the value of the clinical data generated by Napo Therapeutics, in this case for SBS, as reciprocally, Napo Therapeutics receives the value and the ability to utilize the CTD, the cancer phase III data Jaguar is developing.
Hence, the parallel, complementary, and geographically focused development efforts of crofelemer for these two core indications, CTD cancer and SBS, Short Bowel Syndrome, are progressing simultaneously and collaboratively with dedicated teams respectively. Again, a key advantage of the Napo Therapeutics effort to Jaguar is that Napo Therapeutics is well over majority owned by Jaguar, providing potential equity accretion value to Jaguar shareholders and stakeholders, which we believe is unrecognized at this time. Once again, these are the two core pipeline events transforming crofelemer from pipeline to what we believe will be tangible value in the next 12-15 months. An additional key clinical milestone for 2022 is the filing of an investigational new drug, IND, investigational new drug application with the FDA in the mid-year of 2022 this year for symptomatic relief of diarrhea from cholera.
This is for our second-generation anti-secretory called lechlemer. Lechlemer is a different chemical composition of proanthocyanidins extracted from the Croton lechleri tree, which is the same tree from which we get crofelemer, and which we believe defines lechlemer as a distinct product from crofelemer under FDA botanical guidance. By the way, lechlemer has a lower manufacturing cost than crofelemer. Lechlemer works by the same novel anti-secretory mechanism of action as crofelemer. We're planning to initiate a phase 1 lechlemer study in the second half of 2022 for, as I mentioned, the symptomatic relief of diarrhea from cholera. In support of this clinical activity, we received comprehensive animal toxicity preclinical services supported by the National Institute of Allergy and Infectious Diseases, NIAID, NIH basically, for four preclinical studies which have been completed.
We plan to pursue a tropical disease priority review voucher for lechlemer under the FDA's Financial Incentive Program to develop drugs for tropical diseases such as cholera. Priority review vouchers are transferable and in past transactions by other companies have sold for prices ranging from $67 million - $350 million. This therefore provides a potential immediate return on investment upon approval of the product lechlemer for the symptomatic relief of diarrhea from cholera.
On the business development front, as previously announced, this year, we entered an agreement at the end of Q1 with Quadri Pharma that grants Quadri Pharma exclusive promotional commercialization and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, and UAE, and Oman following regulatory approval to market crofelemer in these countries for the specified indications, including the indication currently approved in the United States for HIV-related diarrhea and cancer therapy-related diarrhea, for which crofelemer is currently, as I mentioned, in the pivotal phase III trial. In addition, the agreement grants Quadri Pharma exclusive rights to distribute crofelemer in these countries in the immediate future under named patient programs.
Quadri has knowledge and experience in the distribution of pharmaceutical products throughout the Middle East, including the servicing of requests for a particular medicine in markets where that medicine does not yet have marketing approval, such as requests related to a named patient program, which provides revenue-generating products approved in a major market country such as the United States to individual named patients through physician requests in a country where marketing approval has not yet been granted. According to UNAIDS's 2020 Global Report, the HIV epidemic is growing in the Middle East and North Africa, referred to as the MENA region, with an estimated 20,000 new infections in 2019, a 25% increase over infections in 2010, and an estimated 170,000-400,000 adults and children in the region who lived with HIV in 2019.
This is a revenue-sharing relationship for HIV-related diarrhea in Bahrain, Kuwait, Qatar, Saudi Arabia, UAE, and Oman, and the agreement terms provide Jaguar with an increase in the revenue-sharing percentage for sales in these countries of newly approved indications, which will apply to the CTD and ultimately inflammatory bowel disease indications for crofelemer upon marketing approval. Dr. Karen Brunke, Jaguar's very experienced and capable Executive Vice President of Corporate and Business Development, orchestrated our relationship with Quadri Pharma, and this collaboration is a welcome and important step towards making crofelemer's novel mechanism of action available to patients in need in global markets. Karen is hard at work pursuing additional business development opportunities for crofelemer, which again, we consider a pipeline within a product for multiple potential indications in other key markets outside the United States.
Lastly, I would like to let you all participating today know that we will have a brief Q&A segment at the end of this webcast to address questions, if any, submitted in writing as we normally do. Questions can be submitted via the webcast link for today's event that appears on the Events and Presentations page of the Investor Relations section of Jaguar's website. The URL for Jaguar's website is jaguar.health. I'd also like to point out that the list of analysts that cover Jaguar can also be found on the Investor Relations section of Jaguar's website and includes a new addition this week. We are now being covered and coverage initiation is expected this week. We're now being covered by Ladenburg Thalmann, Cantor Fitzgerald, and just this week, the initiation is expected from CWIC Equity Solutions in conjunction with TAG Investment Bankers.
We'll now move along to key financial results for the first quarter of 2022, and I'll turn it over to Carol.
Thank you, Lisa, and thank you all for joining our webcast today. I'll begin my review of our financials for the first quarter of 2022. Mytesi net revenue during the first quarter of 2022 was approximately $2.6 million and approximately $2.1 million in the fourth quarter of 2021, an increase of approximately $500,000 or approximately 24% quarter-over-quarter and an increase of approximately 112% over Mytesi net revenue in the first quarter of 2021, which totaled approximately $1.2 million. The transition to a closed network of specialty pharmacies, which was completed this past January, resulted in a meaningful reduction in Mytesi distribution costs and a higher average net price.
As part of the process of transitioning to the closed specialty pharmacy network, the third and fourth quarters of 2021 were significantly impacted by the inventory drawdown of approximately 1,300 bottles of Mytesi across the company's third-party logistics warehouse, wholesalers, distributors, and retail stores. Mytesi prescription volume, the metric the company believes to be the best indicator of growth in patient demand, increased 14.6% in the first quarter of 2022 over the Q4 of 2021. Prescription volume differs from invoice sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.
Mytesi gross revenue, a non-GAAP measure, was approximately $3.4 million in the first quarter of 2022 and $3 million in the fourth quarter of 2021, representing an increase of approximately $400 thousand or 13.4% quarter-over-quarter. It was a decrease of approximately 25.5% over Mytesi revenue, gross revenue that is, in the first quarter of 2021, which was approximately $4.6 million. The increase in Mytesi gross revenue in the first quarter of 2022 over the fourth quarter of 2021 is due largely to the fact that infrastructure required to complete the transition to a closed network of specialty pharmacies was not fully in place in the fourth quarter of 2021. The loosening of COVID-related travel restrictions in the first quarter of 2022 allowed Mytesi sales personnel to visit more healthcare providers.
The decrease in Mytesi gross revenue in the first quarter of 2022 as compared to the same quarter in the prior year was due to the process of transitioning to distributing Mytesi through a closed network of specialty pharmacies instead of through wholesalers that resell the product to retail pharmacies. For the first quarter of 2022, the loss from operations was $11.8 million compared to a loss of $8.8 million in the first quarter of 2021. An increase of $3 million quarter-over-quarter, largely due to the increased clinical trial activities related to the company's OnTarget phase III of crofelemer for prophylaxis of cancer therapy-related diarrhea, or what we call CTD, as well as development efforts for other indications.
For the first quarter of 2022, the net loss attributable to common shareholders was approximately $18 million compared to a loss of $12 million in the first quarter of 2021. An increase of $6 million quarter-over-quarter. In addition to the loss from operations, interest expense increased $2.3 million from $1.9 million in the three months ended March 31, 2021 to $4.2 million for the same period in 2022, primarily due to interest from the royalty and note agreement.
The increase in the loss on extinguishment of debt from $753,000 in the three months ended March 31, 2021 to $2.8 million in the same period in 2022 is due to the $2.8 million extinguishment loss from the exchange of the outstanding balance of one of the royalty agreements for shares of the company's common stock. Change in fair value of financial instruments and hybrid instruments designated as fair value option, or FVO. Losses decreased $400,000 from a loss of $600,000 in the three months ended March 31, 2021 to $200,000 for the same period in 2022, designated as FVO, I should say.
Other income increased by $800,000 from $10,000 in the three months ended March 31, 2021 to $800,000 for the same period in 2022 due to the foreign currency transactions. Non-GAAP EBITDA for the first quarter of 2022 and the first quarter of 2021 was a net loss of $9.4 million and $6.8 million, respectively. That concludes my recap of high-level financials for the first quarter of 2022. I will now hand the discussion over to Ian Wendt, Chief Commercial Officer. Ian.
Thank you, Carol, and good morning to all. As Carol stated, Mytesi total prescription volume, the metric we believe to be the best indicator of patient demand, increased 14.6% in the first quarter of 2022 over the fourth quarter of 2021. As previously announced, the transition to a closed network of specialty pharmacies has resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price. In fact, I'm very pleased to report that we significantly outperformed the industry gross to net average in the first quarter of 2022 and the fourth quarter of 2021 for sales of our human prescription product as a result of our transition to the closed network of specialty pharmacies.
A key component of the company's market access strategy, the initiative to transition to a closed network of specialty pharmacies, is intended to help remove access barriers for patients prescribed Mytesi and includes services such as a higher level of support for prior authorizations, appeals, adherence counseling, and home delivery options. While patients often visit retail pharmacies for short-term or uncomplicated medical needs, specialty pharmacies focus primarily on serving patients with complex and chronic medical conditions, like HIV.
Importantly, this transition has also allowed us to begin utilizing sales and prescription data directly provided by our network of specialty pharmacies to more accurately track prescription volume and the patient journey, rather than relying on a third-party provider of estimated data for these important performance metrics, and assist in the preparation of our US commercial distribution network for potential future indication expansion of crofelemer to other populations of patients with complex medical needs, such as CTD and SBS. I'm also pleased to report that we have rolled out new innovative programs that further support identifying appropriate Mytesi patients and connecting them to care and medication access services. The first program is a telehealth initiative, which went live just this past Friday, that enables patients seeking help with their HIV-related diarrhea to be linked immediately to a provider for assistance with their medical needs.
This new capability prevents patients from having to wait until their next scheduled doctor visit to get help with an urgent problem. Our second new program delivers digital Mytesi and disease state education directly into a provider's electronic health record, or EHR system, so that they learn about Mytesi at the moment they are seeing their HIV patients. This technology allows us to intelligently deliver ads to a provider based on the profile of the patient they are seeing in their exam room. Now note this is strictly a one-way communication. We do not actually receive any protected health information around this program. Both of these programs are designed to drive incremental brand awareness among prescribers who have not written for Mytesi previously, and among patients who have not been able to receive immediate care for their HIV-related diarrhea. Now turning to the animal health side of our business.
We are thrilled, as Lisa mentioned, that Canalevia-CA1, our FDA conditionally approved treatment for chemotherapy-induced diarrhea or CID in dogs, became commercially available to veterinarians across the United States at the end of last month. Canalevia-CA1 is an important prescription drug introduction for the veterinary community and the thousands of dogs experiencing CID. As Lisa commented, dogs, as with humans, go off their disease-modifying chemotherapy approximately 40% of the time due to diarrhea. Canalevia-CA1 can help support the comfort and quality of life of dogs while being treated with chemotherapy, which may help them remain compliant with their life-saving treatment. The reception of Canalevia-CA1 among general practice vets and veterinary oncologists who have learned about the product has been extremely positive. Launch activities for Canalevia-CA1 remain underway.
The product was the focus of Jaguar Animal Health's exhibit booth at the recent in April Veterinary Cancer Society mid-year conference, which took place in Puerto Vallarta, Mexico. The company also held a well-attended dinner event for veterinary oncologists about CID in dogs at this conference. Jaguar Animal Health will also be exhibiting at the 2022 American College of Veterinary Internal Medicine or ACVIM forum in Austin from June 22nd to the 25th. As announced, we expect that Canalevia could additionally receive FDA conditional approval under the name Canalevia-CA2 for the treatment of exercise-induced diarrhea, what is termed EID, in dogs in the fourth quarter of 2022, which would be a very fitting way to finish up what we're referring to as Jaguar's year of the dog. That concludes my comments. Thank you for your time today.
I'll now pass the conversation back to Lisa.
Thank you, Ian. Thank you, Carol. Nicely done. We at Jaguar, Napo, and Napo Therapeutics are energized about all of the important initiatives underway in 2022, and in particular, the expectation for what we feel will be transformative value creation in the next 12 - 15 months as we focus on supporting the realization of the value of our crofelemer pipeline. We now open the floor to written questions that have come in, and I will start to pull them up right now. What happened? Okay. My connection to the questions just disappeared, but it's coming back. Peter, if you're online, can you see the questions? Can you read them out to me?
Yep, I can read them out to you. The first question is.
Okay, why don't we do that.
Is there a plan for an upcoming IPO?
Of course, we're a public company, and that must be referring to Napo Therapeutics. Napo Therapeutics has indicated that it would seek liquidity after what we're looking for and they're looking for the value transformative event of completing the proof of concept studies that are published that could support expanded patient access. That liquidity event could take many different forms. Of course, Jaguar is already public and well over the majority of Napo Therapeutics is held in equity in Jaguar. Okay, Peter, I'm still-
Next question. Congrats on the quarter. We saw the statement on the 10-Q regarding your current capital runway. We're interested to know more about your strategy in extending your runway. Can you provide more color here?
That's from Carvey. Hi, Carvey. Okay, I can see the questions now, Peter. You know, money is fungible, money is money, but we do our best to match the expense of our clinical initiatives to non-dilutive dollars. For example, the SBS, of course, is being run by the funds that are in Napo Therapeutics, and Napo Therapeutics has additional fundraising activities going on now. Our cancer program, we match to the royalty deal that we have where we have royalties based on the revenues that are coming in from Mytesi for HIV, a royalty funding program. With some of the business activities that we're planning in 2022 that are initiatives and discussions that have started months, if not years ago, we're looking to continue to bring in non-dilutive dollars to fund our clinical programs.
At this moment, there are no plans to do an extra equity raise or a structured raise at this stock price. Okay. Will we see a big PO for Canalevia for Mars Pet Company this year? Mars, which for people who don't know Mars, the Mars company, the candy bar company, they own VCA and a couple of other major. Their corporate ownership of many clinics. And Ian, you probably know what the number of clinics are throughout the United States and even outside the United States. I'll let you jump in a moment here. They are absolutely a customer, and many of the veterinarians who work and do clinical trials in that network have participated in the presentations that we have done with the education and promotion of Canalevia. Yeah, we expect that there will be sales into the Mars network.
Ian, do you know what the number of vet clinics is in the Mars network?
Yeah, I know in the specialty clinic space, I think they have about 90 - 100, and those would be clinics that include oncology care. The primary care clinics or general practice clinics number into the many hundreds. In fact, I think it might even be approaching 1,000, especially with all the recent acquisitions that they've made. They've bought up a number of large clinic chains or medium to large clinic chains. So they're a huge customer of ours. They actually reached out to us to kick off commercial discussions because they were very interested in stocking Canalevia and adding it to their formulary. We're certainly expecting them to be a large customer.
Terrific. These days, more and more dogs are being treated for cancer at their general veterinary practitioner, not just at specialty clinics, although the specialty research and awareness and education in the oncology specialty clinics is really are the organizations that are cutting edge, and are a focus of our initial efforts for Canalevia education and promotion. I do wanna go back one question to Carvey. Also, I believe everyone's aware that we do have an ATM in place, and that does provide great flexibility for a company like ours if at some point we feel concerned about cash because of excess time or excess expense, for example, in our clinical trials, we can always utilize the ATM. Could you talk a bit more about the Named Patient program? How does it work?
What's the impact it can have on top line in the near medium term? Named patient program is terrific. It's fantastic for patients around the world in countries where there's not clinical approval, regulatory approval in their particular country, but where a major country like the United States has FDA approval. Obviously, for us, it's for the HIV indications. Physicians who become aware of Mytesi can specifically name a patient for which the product can be imported and prescribed and paid for. It is at our WAC price, and in the case of Quadri, it's based on the revenue-sharing model that we talked about. It can provide immediate relief to these patients as the physicians become aware of Mytesi and the need in certain patients while the regulatory process is continuing in the different countries in the MENA region.
I don't see any other questions. Peter, do you see any other questions?
I do not, Lisa. I think we're good on that front.
Okay. I think we're good. Thank you all for participating, and we're very excited about this quarter's results, and we're very excited about the continual performance of Mytesi, Canalevia in 2022, and of course, the SBS and the CTD in the future. Have a wonderful day. Thank you all.
This concludes today's webcast. We thank you again for your participation. You may now disconnect.